• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Dabigatran noninferior to warfarin for VTE

bys25qthea
February 21, 2013
in Chronic Disease
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

Feb 21st – Dabigatran also has a significantly lower incidence of major bleeding events vs. warfarin.

[tabs tab1=”2MM Rundown” tab2= “2MM Full Report”]

[tab]

Image: PD

1. Long term treatment with dabigatran is noninferior to warfarin and superior to placebo at preventing recurrent or fatal venous thromboemobolism (VTE) after 3 months of initial treatment.

2. Dabigatran has significantly lower incidence of major and clinically significant bleeding events than warfarin; however, it significantly increases risk of bleeding compared to placebo.

Published today in the New England Journal of Medicine, this study demonstrates that dabigatran is noninferior to warfarin and superior to placebo in the prevention of recurrent VTE. Importantly, while dabigatran demonstrated a better safety profile in regard to major and minor but clinically significant bleeding, being noninferior to warfarin does not imply equivalent efficacy in prevention of VTE recurrence. The authors’ criteria for noninferiority allows for up to a 2.85 fold increase in recurrence risk before dabigatran is considered to be inferior. In the current study, dabigatran showed a hazard ratio of 1.44 (95%CI, 0.80 to 2.64).  Warfarin is numerically superior in preventing the primary endpoint of recurrent VTE and related death. Additionally, this study and others have demonstrated an increase in acute coronary syndrome events with dabigatran use. While there are clear advantages to dabigatran use, continued evaluation of its efficacy, safety and cost profile in comparison to standard and other novel therapeutics is warranted.

RELATED REPORTS

TRAPS: Rivaroxaban vs. Warfarin for Secondary Prevention in Antiphospholipid Syndrome [Classics Series]

RE-VERSE AD Trial: Idarucizumab for the Reversal of Anticoagulation by Dabigatran [Classics Series]

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

Click to read the study in NEJM

[/tab]

[tab]

Image: PD

1. Long term treatment with dabigatran is noninferior to warfarin and superior to placebo at preventing recurrent or fatal venous thromboemobolism.

2. Dabigatran has significantly lower incidence of major and clinically significant bleeding events than warfarin; however, it significantly increases risk of bleeding compared to placebo.

This [double-blind, randomized] two-part trial sought to determine if dabigatran was noninferior to warfarin and superior to placebo for prevention of recurrent or fatal venous thromboembolism (VTE). Enrolled patients were >18 years old and had been on approved anticoagulant treatment for objectively confirmed proximal deep-vein thrombosis or pulmonary embolism. 2866 patients were randomized to receive either Dabigatran or warfarin for 6 to 36 months; 1353 patients received dabigatran or dabigatran-like placebo for up to 12 months. The primary efficacy endpoint was prevention of recurrent, symptomatic VTE or death related to VTE. Safety analysis looked at major, minor but clinically significant minor bleeding and acute coronary syndrome events.

Compared to warfarin, the hazard ratio for the primary end point of recurrent or fatal VTE was 1.44 (95% CI 0.78-2.64, p=0.01).While dabigatran demonstrated significantly fewer major and clinically relevant bleeding events than warfarin (HR 0.54 (95% CI 0.41-0.71, p<0.001), it was associated with a significantly increased risk of major and minor bleeding events compared to placebo 2.92 (95% CI 1.52-5.60, p=0.001). Acute coronary syndrome was also higher in the dabigatran group when compared to warfarin (rates of 0.9% vs. 0.2%, respectively; p=0.02)

In sum: Long-term anticoagulation with vitamin K antagonists is recommended for patients with venous thromboembolism (VTE) and risk factors for recurrence. However, treatment with warfarin requires extensive monitoring and dose adjustment. Moreover, anticoagulation comes with the inherent risk of bleeding. Unlike warfarin, dabigatran, a direct thrombin inhibitor, is given at a standard dose of 150 mg twice a day and does not require intensive monitoring.  This article comes after a series of trials, RE-COVER and RE-COVER II, which investigated the use of dabigatran for the treatment of VTE. This study investigates the use of dabigatran in the long-term prevention of VTE recurrence.

Published today, this study demonstrates that dabigatran is noninferior to warfarin and superior to placebo in the prevention of recurrent VTE. Importantly, while dabigatran demonstrated a better safety profile in regard to major and minor but clinically significant bleeding, being noninferior to warfarin does not imply equivalent efficacy in prevention of VTE recurrence. The authors’ criteria for noninferiority allows for up to a 2.85 fold increase in recurrence risk before dabigatran is considered to be inferior. In the current study, dabigatran showed a hazard ratio of 1.44 (95%CI, 0.80 to 2.64).  Warfarin is numerically superior in preventing the primary endpoint of recurrent VTE and related death. Additionally, this study and others have demonstrated an increase in acute coronary syndrome events with dabigatran use. While there are clear advantages to dabigatran use, continued evaluation of its efficacy, safety and cost profile in comparison to standard and other novel therapeutics is warranted.

Click to read the study in NEJM

By Jessica Mitchell and Mitalee Patil

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

[/tab]

[/tabs]

Tags: dabigatranVTEwarfarin
Previous Post

Health care costs not reduced after bariatric surgery

Next Post

PCI linked to higher rates of adverse events vs. OPCAB

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Critical, Emergent and Pulmonary Care Classics

TRAPS: Rivaroxaban vs. Warfarin for Secondary Prevention in Antiphospholipid Syndrome [Classics Series]

June 23, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Critical, Emergent and Pulmonary Care Classics

RE-VERSE AD Trial: Idarucizumab for the Reversal of Anticoagulation by Dabigatran [Classics Series]

June 20, 2022
#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19
StudyGraphics

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

January 26, 2022
#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease
StudyGraphics

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

December 16, 2021
Next Post

PCI linked to higher rates of adverse events vs. OPCAB

Shorter telomere length linked with increased risk of common cold

New device reduces acid exposure in gastroesophageal reflux disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.